Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:7454
Structure:
Synonyms:
.alpha.,p-Dibromoacetophenone
.alpha.-p-Dibromoacetophenone
2,4 -Dibromoacetophenone
2,4'-dibromo acetophenone
2,4'-Dibromo-acetophenone
2,4'-Dibromoacetophenone
2,4-dibromoacetophenone
2-Bromo-1-(4-bromo-phenyl)-ethanone
2-bromo-1-(4-bromophenyl)ethan-1-one
2-bromo-1-(4-bromophenyl)ethanone
4'-Bromophenacyl bromide
4-07-00-00652 (Beilstein Handbook Reference)
4-BPB
4-Bromo(bromoacetyl)benzene
4-Bromophenacyl bromide
99-73-0
a,p-dibromoacetophenone
A5501
AC1L1OSP
AC1Q27E1
Acetophenone, 2,4'-dibromo-
AG-I-02352
AI3-52310
AIDS-026799
AIDS026799
AKOS000210402
alpha,4'-Dibromoacetophenone
alpha,4-Dibromoacetophenone
alpha,p-Dibromoacetophenone
alpha-4-Dibromoacetophenone
alpha-para-dibromoacetophenone
ARONIS007671
BRN 0607604
Bromomethyl 4-bromophenyl ketone
Bromomethyl p-bromophenyl ketone
bromophenacyl bromide
bromophenacylbromide
C006821
C8H6Br2O
CCRIS 3623
CHEMBL142826
D0164
D38308_ALDRICH
dibromoacetophenone-2,4
EINECS 202-783-6
Ethanone, 2-bromo-1-(4-bromophenyl)-
F1723-0259
FS000052
GSK-3beta Inhibitor VII
Halomethyl Phenyl Ketone deriv. 24
HSCI1_000166
IN1317
LS-13457
MolPort-000-153-851
NSC 6224
NSC6224
p-.alpha.-Dibromoacetophenone
p-Bromophenacyl bromide
p-Bromophenacyl-8
P-DIBROMOACETOPHENONE
Parabromophenacyl bromide
PBPAB
pbpb
S01-0145
ST001361
STL069069
Tau Protein Kinase I Inhibitor
TL8006077
TOS-BB-1138
TPK I Inhibitor
WLN: E1VR DE
ZINC00028146

Target

show target details
Uniprot ID:DUOX1_RAT
Synonyms:
Dual oxidase 1
EC-Numbers:1.11.1.-
1.6.3.1
Organism:Rat
Rattus norvegicus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

3015312
Inhibition of neutrophil activation by p-bromophenacyl bromide and its effects on phospholipase A2.. R E Duque; J C Fantone; C Kramer; W A Marasco; S H Phan (1986) British journal of pharmacology display abstract
In an effort to elucidate the nature of the inhibitory effects of p-bromophenacyl bromide (pBPB) on neutrophil stimulation, we have examined its effects on several stages of stimulus-response coupling. Pretreatment of rat neutrophils with pBPB resulted in a dose- and time-dependent irreversible inhibition of both N-formylmethionyl-leucylphenylalanine (fMet-Leu-Phe)-induced lysosomal enzyme release and change in transmembrane potential. Inhibition of the biological responses to the chemotactic peptide fMet-Leu-Phe was not due to receptor inactivation since fMet-Leu-[3H]-Phe binding to the formyl peptide receptor was not significantly altered by pBPB pretreatment. Inhibition by pBPB of phorbol myristate acetate (PMA)-induced changes in transmembrane potential and the generation of superoxide (0-2) was also observed. pBPB treatment appeared to inhibit activation of the NADPH oxidase without a direct effect on the oxidase itself. This inhibitory effect was not accompanied by cell death or decrease in cellular titratable sulphydryl groups (at least at doses less than 20 microM). There was, however, significant inhibition of a membranous fraction of fMet-Leu-Phe-induced phospholipase A2 activity by pretreatment with 10 microM pBPB, although total cellular phospholipase A2 was only minimally (less than 20% inhibition) affected. These data would indicate that pBPB inhibits an early event associated with stimulus-response coupling in rat polymorphonuclear leukocytes (i.e. change in transmembrane potential). The inhibitory effects of pBPB may be secondary to the inhibition of a critical membranous fraction of cell bound phospholipase A2 activity or its activation, necessary for the initiation of cell activation.